Schmidt C G
Schweiz Med Wochenschr. 1983 Sep 10;113(36):1293-300.
The prognosis of nonseminomatous germ cell testis tumors has been significantly improved during the past two decades due to progress in cytostatic treatment. General trends and our own long term experience with sequential combination chemotherapy (velbane/bleomycin; adriamycin/cisplatin; ifosfamide/etoposide) in testicular cancer are presented. In disseminated stages survival was closely related to the initial concentration of human chorionic gonadotropin (HCG) and tumor burden (two year survival: more than 80% in patients with minimal pulmonary disease, 40-50% in patients with massive pulmonary disease, and less than 30% in patients with pulmonary metastases and massive retroperitoneal disease). New diagnostic and therapeutic methods to increase survival rates further in nonseminomatous testicular cancer are discussed.
在过去二十年中，由于细胞抑制治疗取得进展，非精原细胞瘤性睾丸肿瘤的预后得到显著改善。本文介绍了总体趋势以及我们在睾丸癌序贯联合化疗（长春花碱/博来霉素；阿霉素/顺铂；异环磷酰胺/依托泊苷）方面的长期经验。在播散期，生存率与人类绒毛膜促性腺激素（HCG）的初始浓度和肿瘤负荷密切相关（两年生存率：肺部疾病轻微的患者超过80%，肺部疾病严重的患者为40 - 50%，肺部转移和腹膜后疾病严重的患者低于30%）。文中还讨论了进一步提高非精原细胞瘤性睾丸癌生存率的新诊断和治疗方法。
